top of page
Platform Technology
Restructured monoclonal antibody with optimally enhanced FcγR avidity
Antibody
T cell engager
ADC
CAR-T
Competing platforms
Low Efficacy
High Combinability
High Safety
Low Safety
Low Combinability
High Efficacy
Our Twin Fc-ICE platform aims to overcome poor
efficacy of antibody drugs in treating cancer as well
as to achieve superior safety to ADC and CAR-T
Twin Fc-ICE
EFFICACY
SAFETY & COMBINABILITY
A simplified view of
Twin Fc-ICE’s MoA
Enhanced Fc
effector functions
Macrophage
Dendritic cell
NK cell
Twin Fc-ICE
Cancer Cells
bottom of page